FDA grants AstraZeneca Farxiga (Dagre Net) rapid-track eligibility for heart failure

recently, AstraZeneca announcedThe FDA(http://granted its Farxiga (Dagre Net) rapid-track eligibility for heart failure, which is used to reduce the risk of cardiovascular death or hospitalization in patients with heart failure with reduced or blood-seeking scoresOn August 27, AstraZeneca also announced that Dagrec had been granted FDA-awarded fast-track eligibility to delay the progression of renal failure and prevent cardiovascular and kidney death risk in patients with chronic kidney diseaseAbout DaglenetDagley Net is a sodium-glucose co-transport protein-2 (SGLT-2) inhibitorSGLT-2 is mainly expressed in the kidneys and is mainly used to help the kidneys reabsorb glucoseSGLT-2 inhibitors reduce the reabsorption of glucose by the kidneys by inhibiting SGLT-2 activity, promoting the release of excess glucose through urine, which in turn plays a role in reducing sugarSGLT-2 inhibitors are non-insulin-dependent sugar-reducing drugs, which are a new way of diabetes treatmentThe mechanism of action of SGLT-2 inhibitors, which are used to treat heart failure, has not yet been fully clarifiedDagrenet also received evidence of cardiovascular benefits from the landmark DECLARE study, and although it was not until the end of this year that new indications of "reducing cardiovascular events in people with type 2 diabetes" could be added to thedrug(http://label, Dagley was well ahead of the competition in terms of the rate at which heart failure toenAstraZeneca data, Farxiga will submit a listing application for heart failure to the FDA in 2020H1